location： Home > Products > Signaling Pathways > Neuronal Signaling > COX

Bromfenac Sodium (AHR 10282R)

Price：

Market Price：

This product is for research use only, not for human use. We do not sell to patients.

Number： - + Pieces（InventoryPieces）

InvivoChem Cat #: V1048

CAS #: 91714-93-1Purity ≥98%

Description: Bromfenac Sodium (formerly AHR-10282R; AHR10282R; AHR-10282, AHR10282; trade names Prolensa, Bromday, Xibrom), an approved nonsteroidal anti-inflammatory drug (NSAID), is an orally bioavailable COX-1/2 inhibitor with anti-inflammatory activity. It can inhibit the biosynthesis of prostaglandin by blocking cyclooxygenase 1 and 2.

References: Arzneimittelforschung. 1987 May;37(5):513-9; Drug Metab Dispos. 1998 Jul;26(7):720-3.

Related CAS #: 91714-93-1 (sodium); 91714-94-2 (free acid)

Customer Validation

Top Publications Citing Invivochem Products

详情页公告 Product Catalog 2022

Bulletin Board

详情页公告 Guide to Product Handling

Publications Citing InvivoChem Products

Physicochemical and Storage Information
Protocol
Quality Control Documentation
Related Biological Data
Customer Review

Molecular Weight (MW)	356.15
Formula	C15H11BrNO3.Na
CAS No.	91714-93-1
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 71 mg/mL (199.4 mM)
	Water: 71 mg/mL (199.4 mM)
	Ethanol: 2 mg/mL (5.6 mM)
Other info	Chemical Name: 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium InChi Key: HZFGMQJYAFHESD-UHFFFAOYSA-M InChi Code: InChI=1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1 SMILES Code: O=C(O)CC1=CC=CC(C(C2=CC=C(Br)C=C2)=O)=C1N
Synonyms	AHR 10282R; Bromfenac sodium, Prolensa, AHR-10282R; AHR10282R; Bromday, Xibrom, AHR-10282, AHR10282, AHR 10282

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
- Mass
- Concentration
- Volume
- Molecular Weight *
- =
- ×
- ×
The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂
- Concentration _(start)
- ×
- Volume _(start)
- =
- Concentration _(final)
- ×
- Volume _(final)
- ×
- =
- ×
- C1
- V1
- C2
- V2

In Vitro	In vitro activity: N/A
In Vivo	Bromfenac (bromfenac sodium) by the oral route at pretreatment times of 10 min, 20 min and 300 min is respectively 3.7, 6.5 and 2.9 times more potent than zomepirac and 3.4, 6.6, and 44.2 times more potent than suprofen in the acetylcholine abdominal constriction assay in mice. Bromfenac when given orally is 5.8 times more potent than zomepirac in blocking the nociceptive response to bradykinin in dogs. Bromfenac is 6.1 to 32.8 times more potent than indometacin in inhibiting the formation of prostaglandin E2 and F2 alpha from microsomes of bovine seminal vesicles, rabbit uteri, and rabbit renal medullae. Bromfenac, given orally, is more potent than indometacin in suppressing acute (7.5-20 times) and chronic (3.8 times) inflammation in mice. Bromfenac (1 mg/kg, i.v.) is metabolited into an unusual conjugate, bromfenac N-glucoside, in rats bile. Bromfenac shows a rapid onset of activity (20 min) that persisted for at least 4 hours in a mouse model of pain (acetylcholine abdominal constriction). Bromfenac (0.316 mg/kg) produces significant anti-inflammatory activity up to 24 hours after dosing in a rat model of inflammation (carrageenan foot edema). Bromfenac is readily absorbed after oral administration, peak plasma levels being achieved at the earliest time tested: 20 min in the mouse and 30 min in the rat.
Animal model	Mice, rats, dogs
Formulation & Dosage	N/A
References	Arzneimittelforschung. 1987 May;37(5):513-9; Drug Metab Dispos. 1998 Jul;26(7):720-3.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Purity ≥ 98%
COA
MSDS

Home Prev Next Last page / pices

发评论

Your information is safe with us. * Required Fields.

Product name

Cat

Applicant name

Email address

Phone number

Organization name

Country

Requested quantity

Remarks